Page 1,624«..1020..1,6231,6241,6251,626..1,6301,640..»

Consumption of legumes associated with lower risk of diabetes – Medical Xpress

Posted: March 30, 2017 at 1:40 pm

March 30, 2017 Compared to individuals with a lower consumption of total legumes -- lentils, chickpeas, beans and peas -- individuals with a higher consumption had a 35% lower risk of developing type 2 diabetes. Credit: CSIRO

Legumes are a food group rich in B vitamins, contain different beneficial minerals (calcium, potassium and magnesium) and sizeable amounts of fibre and are regarded as a low-glycemic index food, which means that blood glucose levels increase only slowly after consumption. Due to these unique nutritional qualities, eating legumes regularly can help improve human health. In fact, the Food and Agriculture Organization of the United Nations (FAO) declared 2016 as the international year of legumes to raise people's awareness of their nutritional benefits.

Although legumes have long been though to offer protection against type 2 diabetes (which is a significant health problem worldwide affecting more than 400 million adults in 2015), to date there has been little research to confirm this association.

To increase the general level of knowledge in this area, researchers from the URV's Human Nutrition Unit in collaboration with other research groups in the PREDIMED study evaluated the association between the consumption of the different sub-types of non-soy legumes and the risk of type 2 diabetes among individuals at high cardiovascular risk. They also evaluated the effect of replacing other protein- and carbohydrate-rich foods with legumes on the development of the disease.

Researchers analysed 3349 participants at high risk of cardiovascular disease but without type 2 diabetes at the beginning of the PREDIMED study. After 4 years of follow-up, the results have revealed that compared to individuals with a lower consumption of total legumeslentils, chickpeas, beans and peas- (12.73 grams/day, approximately equivalent to 1.5 servings per week of 60g of raw legumes), individuals with a higher consumption (28.75 grams/day, equivalent to 3,35 servings/week) had a 35% lower risk of developing type 2 diabetes. Of the different subtypes of legume, lentils in particular were associated with a lower risk of type 2 diabetes. Those participants who had a higher consumption of lentils during the follow-up (nearly 1 serving/week) compare to those individuals with a lower consumption (less than half a serving per week), had a 33% lower risk of developing the disease. The researchers also found that the effect of replacing half a serving/day of foods rich in protein or carbohydrates, including eggs, bread, rice and baked potato, for half a serving/day of legumes was also associated with a lower risk of type 2 diabetes incidence.

The researchers highlight the importance of consuming legumes to prevent chronic diseases such as diabetes, but state that further research must be conducted in other populations to confirm these results.

Explore further: Consuming saturated animal fats increases the risk of type 2 diabetes

More information: Nerea Becerra-Toms et al, Legume consumption is inversely associated with type 2 diabetes incidence in adults: a prospective assessment from the PREDIMED study, Clinical Nutrition (2017). DOI: 10.1016/j.clnu.2017.03.015

Provided by: Universitat Rovira i Virgili

Recently, dietary guidelines for the general population have shifted toward a plant-based diet rich in legumes, whole-grain cereals, fruits, vegetables and nuts, and low in animal-based foods like red meat. Increasing evidence ...

Eating more gluten may be associated with a lower risk of developing Type 2 diabetes, according to research presented at the American Heart Association's Epidemiology and Prevention / Lifestyle and Cardiometabolic Health ...

Consuming a plant-based dietespecially one rich in high-quality plant foods such as whole grains, fruits, vegetables, nuts, and legumesis linked with substantially lower risk of developing type 2 diabetes, according ...

Eating just 1 serving daily of legumes such as beans, chickpeas, lentils and peas can significantly reduce "bad cholesterol" and the risk of heart disease, found a study published in CMAJ (Canadian Medical Association Journal).

Eating more legumes (such as beans, chickpeas or lentils) as part of a low-glycemic index diet appears to improve glycemic control and reduce estimated coronary heart disease (CHD) risk in patients with type 2 diabetes mellitus ...

Women who eat more potatoes before pregnancy may have higher rates of gestational diabetesthe form that occurs during pregnancycompared to women who consume fewer potatoes, suggests a National Institutes of Health (NIH) ...

Scientists may have found a new tool for studyingand maybe even treatingType 2 diabetes, the form of diabetes considered responsible for close to 95 percent of cases in the United States.

With a series of new grants, Saint Louis University researchers will tackle the twin epidemics of diabetes and obesity by tapping into the potential of two nuclear receptors that control muscle metabolism. The scientists ...

For parents, storing their newborn baby's umbilical cord blood is a way to preserve potentially lifesaving cells. Now, a group of University of Florida Health researchers has found a way to expand and preserve certain cord-blood ...

How do mammals keep two biologically crucial metabolites in balance during times when they are feeding, sleeping, and fasting? The answer may require rewriting some textbooks.

Daily screen time of three or more hours is linked to several risk factors associated with the development of diabetes in children, finds research published online in the Archives of Disease in Childhood.

Jason Dyck has long believed in the beneficial properties of resveratrola powerful antioxidant produced by some plants to protect against environmental stresses. The professor of pediatrics at the University of Alberta ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the rest here:
Consumption of legumes associated with lower risk of diabetes - Medical Xpress

Posted in Diabetes | Comments Off on Consumption of legumes associated with lower risk of diabetes – Medical Xpress

Low-cost diabetes prevention program coming to Tahoe Forest Health System – Sierra Sun

Posted: March 30, 2017 at 1:40 pm

Have you been diagnosed with prediabetes? Do you have a family history of diabetes that you fear may impact you in the future?

Often times, doctors like to "watch" patients who have risk factors for diabetes, including being overweight and having slightly elevated blood sugars, because there hasn't been a place for these patients to learn more on how to stay well until now.

The Wellness Neighborhood of Tahoe Forest Health System is proud to offer Prevent T2, part of the CDC-recognized National Diabetes Prevention Program that has been shown to help at-risk adults cut their risk for developing type 2 diabetes by 58%.

Beginning in April, a Registered Dietitian Nutritionist will be leading the Prevent T2 lifestyle change program at Tahoe-Truckee at low cost for participants. A payment plan will also be available.

This program is unique in that it targets people who do not have diabetes, and who even may not have been told by a doctor that they have prediabetes.

Did you know that roughly one in three American adults has prediabetes, and many don't know it? People with higher-than-normal blood glucose (sugar) levels are 5-15 times more likely to develop type 2 diabetes than those with normal blood glucose levels.

In fact, many people with prediabetes can be diagnosed with type 2 diabetes within 5 years.

The Prevent T2 program offers a proven approach to preventing or delaying the onset of type 2 diabetes through modest lifestyle changes made with the support of a coach and one's peers.

Participants will learn how to eat healthy, add physical activity to their routine, manage stress, stay motivated, and solve problems that can get in the way of healthy changes. The group will meet for a year weekly for the first 6 months, then once or twice a month for the second 6 months to maintain healthy lifestyle changes.

The program's group setting provides a supportive environment with people who are facing similar challenges and trying to make the same changes. Together participants celebrate their successes and find ways to overcome obstacles.

To find out if you are at risk for, or may have, prediabetes, take the risk test (available in English and Spanish) at doihaveprediabetes.org or visit your primary care physician to get the appropriate screening blood tests.

You do not need a referral from you medical provider to participate in the Prevent T2 program, but you do need to qualify based on eligibility criteria (overweight and elevated blood sugars or a previous diagnosis of gestational diabetes) or a score of 5 or higher on the risk test noted above.

To learn more about the Tahoe Forest Prevent T2 program, contact the Center for Health and Sports Performance at 530-587-3769.

Dana Dose, RDN, LD, CDE. Dana is part of the Rethink Healthy team and provides nutrition counseling as well as clinical dietitian services for the Tahoe Forest Health System. Dana will be the trained lifestyle coach for the upcoming Prevent T2 Diabetes Prevention Program.

Read the original here:
Low-cost diabetes prevention program coming to Tahoe Forest Health System - Sierra Sun

Posted in Diabetes | Comments Off on Low-cost diabetes prevention program coming to Tahoe Forest Health System – Sierra Sun

How ESPN’s radio host Mike Golic controls his type 2 diabetes – Fox News

Posted: March 30, 2017 at 1:40 pm

As a former NFL player, ESPNS Mike Golic is used to talking sports news and game drama on his radio show Mike and Mike in the Morning. Now, he's discussing a more serious topic, type 2 diabetes. Since being diagnosed with the disease 12 years ago, Golic has been on a mission to raise awareness and help people learn how to manage their blood sugar.

My advice to people with type 2 diabetes is get everybody involved in your life. Its not something to run from, hide from, [and] keep it a secret from everybody else. Youve been diagnosed with it, you have to deal with it, Mike Golic, now 54, told Fox News.

Golic admitted that during his time as a defensive lineman he never thought anything could be physically wrong with him other than a few bruises or tears. But in the back of his mind, he knew his father had type 2 diabetes, which raised his risk.

While it was a, Oh man there was like a Yeah, OK, my dad was right about this age when he was diagnosed, so while it was surprising it wasnt shocking, he said.

According to the National Institute of Health (NIH), having a parent or sibling with the disease can increase your risk. Other risk factors include being overweight, having an unhealthy diet and high blood pressure.

Growing up, Golic said his father kept his condition to himself and didnt talk about it with his family.

It was just kind of his thing to deal with, he said. But I wanted to be very proactive and involve my wife, involve my family, I have three kids [and] two boys are large football players whose grandfather had type 2 diabetes and I have type 2 diabetes, so I wanted to keep them in the loop on this and what needed to be done."

After teaming up with Janssen Pharmaceuticals, Golic and his doctors came up with a game plan to keep his blood sugar levels in check. Type 2 diabetes can be treated with a variety of different medications. He turned to INVOKANA (canagliflozin), a prescription medicine his doctor recommended.

In addition to medicine, eating healthy and regularly exercising can also help manage the disease.

If left untreated, type 2 diabetes can cause serious and even deadly complications.

You can have retinopathy or eye disease, you can have kidney disease and ultimately it can lead to kidney failure and you can have neuropathy which is a disease of the nerve ending which ultimately can cause amputations, Dr. John Anderson, a board-certified Internist at Frist Clinic in Nashville, Tenn., told Fox News. Youre also a 2- to 3-fold increase risk of heart attack and stroke.

Early diagnosis should be accessible during routine exams or physicals when physicians check a patients blood sugar level. But other signs and symptoms may include thirst, frequent urination, blurred vision, fatigue and weight loss, Anderson said.

We have about 89 million people in the country with prediabetes, that means their numbers are not quite in the range that youd diagnose diabetes but theyre on their way, Anderson who is a long-time volunteer for the American Diabetes Association (ADA), and has served as Chair of National Advocacy said. Thats why you need to be seeing your health care professional, getting your screenings, getting your glucoses checked, being proactive.

Today, Golic gets his A1C1 test, a blood test that measures the average level of glucose in the blood,every three-to-four months and has kept his diabetes under control.

This is a situation that can have some complications in your life if you dont treat it the right way, so why not get people involved, why not start with your doctor OK this is the game plan, and then you go to the people in your family this is the game plan my doctor gave me, this is what I need to do and I need all your help to do it, Golic said.

For more information visit ICanImagine.com.

Read more:
How ESPN's radio host Mike Golic controls his type 2 diabetes - Fox News

Posted in Diabetes | Comments Off on How ESPN’s radio host Mike Golic controls his type 2 diabetes – Fox News

IShares Nasdaq Biotechnology Index: Short the Near-Term Action in … – Investorplace.com

Posted: March 29, 2017 at 2:46 am

By Nicolas Chahine, InvestorPlace Contributor|Mar 28, 2017, 11:13 am EDT

It would seem that the toxicity that the iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB) were suffering on Wall Street is waning. Until recently, the political headlines were a threat to all healthcare and biotech stock holders.The thesis that biotech stocks are untouchable, however, is no longer the dark cloud that it was.

So can I buy the IBB long from here with confidence? Not in my opinion. I think that trading the IBB should fit into a bullish macro scenario, which we may no longer have. Equity markets are near all-time highs with few catalysts that are not yet priced in. Traders quickly priced in the fiscal spending and legislative advantage that President Trump promised. This week we saw the first promise die, so the onus is now on the bulls to prove they can deliver the rest.

Click to EnlargeSo to say the least, the perfectly bullish scenario has some rebuilding to do. This creates an opportunity to take a short-term bearish bet on the IBB. I can do this without spending any out-of-pocket money.

Before you label me a bear, I am merely shorting the near-term price action and not the fundamentals of any components within the IBB. In fact, I will leverage their value to pay for my bet.

The Trade: Buy the IBB June $280/$275 debit put spread for $1.30. This is a bearish trade that could triple my money if IBB falls through my spread before mid-June. The cost of entry is my maximum potential loss. I usually like to hedge my bets, and in this case, I will sell downside risk against the value of the IBB. The trick is to find proven support zones.

The Bank: Sell the IBB Jan $200 put and collect $3 per contract. The current 30% price buffer gives this leg a 90% theoretical chance of success. As long as IBB stock stays above my January sold strike, any premium I recover from selling the June debit put spread would be pure profit. Having no out-of-pocket risk makes managing this trade relatively easy.

Fair warning: Selling puts is risky, so only do it if you are willing and able to own the IBB shares at the strike price.

Nicolas Chahine is the managing director of SellSpreads.com. Learn options as easy as 1-2-3 here. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him on Twitter at @racernicand stocktwits at@racernic.

Article printed from InvestorPlace Media, http://investorplace.com/2017/03/short-the-ishares-nasdaq-biotechnology-index-etf-ibb-etf/.

2017 InvestorPlace Media, LLC

Read the original here:
IShares Nasdaq Biotechnology Index: Short the Near-Term Action in ... - Investorplace.com

Posted in Biotechnology | Comments Off on IShares Nasdaq Biotechnology Index: Short the Near-Term Action in … – Investorplace.com

Agricultural Biotechnology: Emerging Technologies and Global Markets – Yahoo Finance

Posted: March 29, 2017 at 2:46 am

NEW YORK, March 27, 2017 /PRNewswire/ -- Use this report to:- Analyze existing and future agricultural biotechnology products and technologies that will be commercially important. - Receive a qualitative and quantitative description of the agricultural biotechnology industry. - Highlight key market and industry trends, as well as quantify the main market segments. - Receive information on agricultural biotechnologies, market applications, industry structure and competitive dynamics.

Highlights- The global market for agricultural biotechnology reached $29.2 billion in 2016. This market should reach $32.1 billion in 2017 and $53.7 billion in 2022, with a compound annual growth rate (CAGR) of 10.8%. - Genomic-enabled products as a segment reached $24.1 billion in 2016, and should reach nearly $26.5 billion in 2017 and $43.7 billion in 2022, with a CAGR of 10.6%.

STUDY GOALS AND OBJECTIVES BCC Research's goal for this study is to determine the specific applications and forecast global market demand for agricultural biotechnology products over a five-year period from 2017 through 2022. The main objective is to characterize and quantify the agricultural biotechnology products market by product type, geography, and purpose. In addition, the report analyzes the industry structure, competitors, strategic alliances, and intellectual property landscape. A total of 70 companies in the industry are profiled.

Agricultural biotechnology markets analyzed in this report include biotechnology tools, genomics enabled products, and biologicals. Biotechnology tools include DNA sequencing, biochips, RNA interference, synthetic biology, and genome editing. Genomics enabled products include biotech seeds and synthetic biology-enabled products. Biologicals include biopesticides, biostimulants, and genetic biologicals.

A key objective of the report is to provide a comprehensive analysis of the agricultural biotechnology industry, with an emphasis on products and technologies that are commercially important in the 2017 to 2022 time-period. Market segments with rapid growth rates are highlighted, as well as those segments with large market potential. This analysis provides a quantitative basis and market context for companies to make strategic choices about participation in the agricultural industry.

The study will be particularly useful to those companies developing new genomics or proteomics technologies; discovering and development novel seed traits; doing plant breeding; interested in using novel biotechnologies in agriculture; or working inadvanced biotechnology fields like genome editing, synthetic biology, RNA interference, biochips, or DNA sequencing.

The study will also be useful to government agencies or institutions that are developing strategic initiatives for a country's agriculture policy and/or industry.

REASONS FOR DOING THE STUDY

Agriculture is a fundamental and strategic component for a country. As a result, agricultural technologies provide competitive geographic advantage and are highly desirable. Biotechnologies address the pressing industry need for higher crop yields. Agricultural biotechnology is a key and growing component of the global agriculture industry and is thus of interest to a wide audience.

This report seeks to provide a qualitative and quantitative description of the agricultural biotechnology industry so that emerging market opportunities can be identified and exploited by the reader.

The report does this by examining the main product applications and markets, helping companies to prioritize product opportunities and strategic opportunities. The report highlights key market and industry trends, as well as quantifying the main market segments. The reader is thus able to better understand industry structure and changes occurring in the industry.

Rapid changes in technology-intensive fields such as DNA sequencing, genome editing, and synthetic biology are driving new products and applications in agriculture. These developments create unique market opportunities. This report analyzes these trends and their impact on future markets for agricultural products.

Based on these market and technology dynamics, it is especially timely to examine the agricultural biotechnology industry.

INTENDED AUDIENCE

Read More

This study examines and analyzes existing and future agricultural biotechnology products and technologies that will be commercially important.

Markets are presented by product type, crop type, and geographical region. Important market segments covered include the main biotechnologies (DNA sequencing, biochips, RNA interference, synthetic biology tools, and genome editing tools) as well as synthetic biology-enabled chemicals and biofuels, biotech seeds, and biologicals.

In-depth coverage is provided for agricultural biotechnologies; growth driving forces; market applications; industry structure and competitive dynamics; companies and industry alliances; future market potential and product sales forecasts for the period 2017 through 2022. The report forecasts the future value of agricultural biotechnology products by product type and geography.

This report will be of particular interest to agriculture, chemicals, bio-energy, and biotechnology companies; as well as suppliers of genomics tools, synthetic biology, RNA interference, and DNA sequencing products. It will also be of interest to professionals within governments, think tanks, and regulatory agencies to understand the end uses of these technologies in agriculture.

SCOPE AND FORMAT

The study scope includes key agricultural biotechnology tools (i.e., next generation DNA sequencing, biochips, RNA interference, synthetic biology tools and genome editing tools); synthetic biology-enabled chemicals and biofuels; biotech seeds; and biologicals.

BCC analyzes these technologies and products to determine present and future market sizes, and forecasted growth from 2017 through 2022. The report also discusses industry strategic alliances, industry structures, competitive dynamics, patent status, and market driving forces.

BCC provides in-depth coverage of the agricultural biotechnology industry structure, including genomics technology providers (e.g., genome editing, NGS, microarray companies); major seed companies; biotech traits companies; synthetic biology tools companies; companies developing plant feedstocks; and agricultural biologicals companies. It provides an in-depth analysis of major industry acquisitions and alliances during 2015 and 2016.

70 agricultural and biotechnology companies are profiled in this report.

METHODOLOGY

BCC Research examined key users and producers in each of the enduser market segments and technology fields that will be commercially important during the next five years. Discussions with industry thought leaders, as well as secondary market research was performed.

Based on our analysis, we project the future applications of agricultural biotechnologies in the major enduser market segments and by technology type, and forecast sales revenues for 2017 through 2022.

INFORMATION SOURCES

BCC Research performed primary and secondary research for this report. Primary sources included key industry companies and leading research institutions. In addition, data were compiled from secondary sources, including company websites and industry, trade and government publications. Read the full report: http://www.reportlinker.com/p0958100-summary/view-report.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/agricultural-biotechnology-emerging-technologies-and-global-markets-300429907.html

Here is the original post:
Agricultural Biotechnology: Emerging Technologies and Global Markets - Yahoo Finance

Posted in Biotechnology | Comments Off on Agricultural Biotechnology: Emerging Technologies and Global Markets – Yahoo Finance

Buy, Sell or Hold? Analysts Approach: Innoviva (INVA), Puma … – The USA Commerce

Posted: March 29, 2017 at 2:46 am

Buy, Sell or Hold? Analysts Approach: Innoviva (INVA), Puma ...
The USA Commerce
Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) dropped -2.02% to $38.90. During the trading on 03/27/2017, Company's stock ranged from $39.70 to ...
Puma Biotechnology Inc (NASDAQ:PBYI) Broker Price Targets For ...Fiscal Standard
Watch List: Puma Biotechnology Inc (NASDAQ:PBYI) , Red Rock ...NYSE Journal (press release)

all 3 news articles »

Read this article:
Buy, Sell or Hold? Analysts Approach: Innoviva (INVA), Puma ... - The USA Commerce

Posted in Biotechnology | Comments Off on Buy, Sell or Hold? Analysts Approach: Innoviva (INVA), Puma … – The USA Commerce

BIOTECanada: Federal Budget Strengthens Biotechnology Industry Ecosystem Building Canadian Economy – Yahoo Finance

Posted: March 29, 2017 at 2:46 am

OTTAWA, Ontario--(BUSINESS WIRE)--

Canada's biotech industry today welcomed the federal budget and its measures supporting the advancement of Canadian innovation in biotechnology centered sectors such as health/bio-sciences, clean technology and agri-food. Importantly the budget proposes support for the acceleration of innovation through the establishment of sector specific superclusters, including health/bio-sciences, agri-food and clean technology.

"The core of our industry is innovation - much of it coming out of universities. The Budgets focus on innovation and creating super clusters in biotechnology centered fields including health/bio-sciences, agri-food, and clean technology recognizes Canadas strengths in these areas and the enormous opportunity for the economy in successfully advancing biotechnology innovation. Today's commitments will result in products and therapies of the future and will accelerate the use of biotechnology in supporting the global competitiveness of Canadas traditional cornerstone economic sectors of agriculture, forestry, mining, energy and advanced manufacturing," commented Andrew Casey, President and CEO BIOTECanada.

Drawing on the nation's rich legacy of research, Canada now has an opportunity to become one of the worlds most successful modern biotech regions by transitioning its traditional industries into the new economy while drawing on its considerable strength of its investment in research. From universities, small mid-sized companies, hospitals and public research agencies across the country, Canadian biotech scientists make up the ecosystem ensuring Canadas biotechnology sector thrive.

Importantly, Canada already has in place many of the components necessary for global competitiveness and success in biotechnology. Indeed, Canada is home to a number of regional clusters which bring together: world-class universities and research institutes; biotech entrepreneurs; a significant multinational industry presence; and, a highly educated workforce. All told, the Canadian national biotech ecosystem is an economic strength that positions Canada well to compete in the emerging global bio-economy. The Budget will help harness many of these strengths to accelerate Canadas biotechnology innovation progress.

BIOTECanada looks forward to working with the federal government over the months ahead, offering a coordinated set of recommendations and mechanisms for the announced programs. Implementation consultations are key to ensuring the commitments realize the potential they offer to the biotechnology industry.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170322006371/en/

Read more from the original source:
BIOTECanada: Federal Budget Strengthens Biotechnology Industry Ecosystem Building Canadian Economy - Yahoo Finance

Posted in Biotechnology | Comments Off on BIOTECanada: Federal Budget Strengthens Biotechnology Industry Ecosystem Building Canadian Economy – Yahoo Finance

Sheriff: Crushed up medicine, paraphernalia found in inmate’s cell … – wivb.com

Posted: March 29, 2017 at 2:45 am

WARSAW, N.Y. (WIVB) An inmate at the Wyoming County Jail was charged with having contraband in her cell during a search.

Nicole Sullivan, 31, was serving time for criminal possession of a hypodermic instrument when the Wyoming County Sheriffs office says crushed up medication was found in her cell.

In addition to that, the Sheriffs office says paraphernalia used to inhale the medication was also found.

After this, Sullivan was charged with promoting prison contraband. She was arraigned in Village of Warsaw Court and held on $500 bail.

WIVB.com provides commenting to allow for constructive discussion on the stories we cover. In order to comment here, you acknowledge you have read and agreed to our Terms of Service. Commenters who violate these terms, including use of vulgar language or racial slurs, will be banned. Please be respectful of the opinions of others. If you see an inappropriate comment, please flag it for our moderators to review. Note: Comments containing links are not allowed.

See the rest here:
Sheriff: Crushed up medicine, paraphernalia found in inmate's cell ... - wivb.com

Posted in Cell Medicine | Comments Off on Sheriff: Crushed up medicine, paraphernalia found in inmate’s cell … – wivb.com

Local Doctor Working To ‘Brew Blood’ To Combat Certain Disorders – CBS Boston / WBZ

Posted: March 29, 2017 at 2:45 am

March 28, 2017 6:44 PM By Dr. Mallika Marshall

BOSTON (CBS) An everyday problem in the medical community is a lack of blood donations which are needed for transfusions worldwide.

Aware of this issue, scientists are working on a procedure that could brew blood to help combat certain blood disorders.

Scientists work on brewing blood to end lack of blood supply. (WBZ-TV)

As a child in Jamaica, Claud DAguilar was diagnosed with sickle cell disease. Its something thats genetic. It starts from birth so basically youre going through this forever and ever. Amen. Until you die.

Sickle cell disease causes red blood cells to become curved and rigid, leading to severe pain.

Hell on wheels, explained DAguilar. The most excruciating pains you could think about. Something I wouldnt wish on my worst enemy.

Anemia is another common complication and often requires multiple blood transfusions. Thats where George Murphy, PhD, a stem cell scientist at the Center for Regenerative Medicine at Boston Medical Center, enters the picture.

Dr. George Murphy, stem cell scientist, explains the brewing blood process. (WBZ-TV)

We like to actually work on diseases that directly impact this under-served community, one of which is sickle cell disease, said Murphy.

He and his team are working on growing personalized blood cells in the lab that could one day help patients like DAguilar.

In essence, sort of brew blood, said Murphy.

Blood being brewed in lab. (WBZ-TV)

Using a small sample of a patients own blood, scientists can reprogram red blood cells back into master stem cells and then coax them back into red blood cells that are unique to that patient. They can then grow the red blood cells over and over again in the lab.

We could actually make a stem cell line from those particular patients who suffer from sickle cell disease, says Murphy.

Such personalized blood could meet a patients transfusion demands and even reduce the effects of the disease. DAguilar said that would be a win.

Scientist rotates brewed blood in sac. (WBZ-TV)

Not only for me but other people suffering, he said. That would be a godsend.

The process could assist millions of people worldwide who need blood products.

You could actually make a universal supply of blood that could be transfused into anyone, says Murphy.

Although not ready for prime time yet, stem cell derived blood could be available for transfusions in the general population, as Murphy says, Sooner than you think.

Follow Dr. Mallika Marshall on Twitter Mallika Marshall, MD, is an Emmy-award winning journalist and physician who serves as the regular Health Reporter at WBZ-TV in Boston. A practicing physician who is Board Certified in both internal medicine a...

Visit link:
Local Doctor Working To 'Brew Blood' To Combat Certain Disorders - CBS Boston / WBZ

Posted in Cell Medicine | Comments Off on Local Doctor Working To ‘Brew Blood’ To Combat Certain Disorders – CBS Boston / WBZ

Cell Therapy Manufacturing Market, 2027: Partnerships / Collaborations have been Widespread and will Continue to … – GlobeNewswire (press release)

Posted: March 29, 2017 at 2:44 am

March 28, 2017 10:55 ET | Source: Research and Markets

Dublin, March 28, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Cell Therapy Manufacturing Market, 2017-2027" report to their offering.

During the course of our study, we identified over 110 organizations that are actively involved in the manufacturing of cell therapies.

The scope of this report primarily includes manufacturing of advanced therapy medicinal products (ATMPs) that involve the use of immune cells such as T-cells, Tregs, dendritic cells, tumor cells and NK cells, and stem cells such as adult stem cells, human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).

Several players, including cell therapy developers, research institutes, contract manufacturing organizations, and government and non-profit organizations, are playing a critical role in the development and manufacturing of these cell therapies. In fact, a number of these players have made heavy investments to expand their existing capabilities and establish new facilities for cell therapy products in order to meet the increasing demand.

Additionally, stakeholders have received significant support from governments worldwide, in terms of funding and establishment of consortiums to accelerate the transition of these therapies from laboratories to clinics. It is important to highlight that companies that offer logistics and operational services have developed systems / tools for safer and quicker delivery of therapies from manufacturing sites to patients; this has been identified as one of the key challenges in the overall development process.

Popular examples of approved cell-based therapies include (in order of their year of approval) Carticel, CreaVax-RCC, JACE, ReliNethra, PROVENGE and Prochymal. In addition, over 500 cell-based therapy candidates are currently in different stages of clinical development; these are being evaluated in over 1,000 active clinical studies in various regions across the globe. The growing number of cell therapy candidates, coupled with their rapid progression through the various phases of clinical development, continues to create an increasing demand for facilities that offer manufacturing services for these therapies.

The market already has a wide array of well-established players, mid-sized companies and start-ups. Several industry players as well as academic institutes are significantly contributing to the production of GMP grade cell types. In addition, the market has witnessed the entry of several players that offer novel technology solutions, aimed at improving and upgrading existing cell-based therapies and their manufacturing processes. We have observed that such players have signed multiple partnerships / collaborations with an aim to optimize, scale-up and expand the capabilities for production of cell-based therapies.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. CELL THERAPY MANUFACTURING: INTRODUCTION 3.1. Context and Background 3.2. Cell-based Therapies: Introduction 3.3. Cell Therapy Manufacturing: An Introduction 3.4. Cell-based Therapies Manufacturing: Key Challenges 3.5. Cell Therapy Manufacturing: Types of Manufacturers 3.6. Cell Therapy Manufacturing: Other Important Considerations 3.7. Cell Therapy Manufacturing: Regulatory Landscape

4. MARKET OVERVIEW 4.1. Chapter Overview 4.2. Cell Therapy Manufacturing: Overall Market Landscape 4.3. Cell Therapy Manufacturing: Role of Logistic Service Providers

5. ROADMAPS: POTENTIAL STRATEGIES TO OVERCOME EXISTING CHALLENGES 5.1. Chapter Overview 5.2. Roadmap for the United States 5.3. Roadmaps for Other Geographies

6. CELL THERAPY MANUFACTURING: IN-HOUSE MANUFACTURERS 6.1. Chapter Overview 6.2. Argos Therapeutics 6.3. Bavarian Nordic 6.4. Cytori Therapeutics 6.5. Juno Therapeutics 6.6. MEDIPOST 6.7. SOTIO (Acquired by PPF Group) 6.8. Stemedica Cell Technologies

7. CELL THERAPY MANUFACTURING: INDUSTRY PLAYERS 7.1. Chapter Overview 7.2. Cell and Gene Therapy Catapult 7.3. CELLforCURE 7.4. Lonza 7.5. PharmaCell 7.6. PCT, a Caladrius Company 7.7. Roslin Cell Therapies 7.8. Waisman Biomanufacturing

8. CELL THERAPY MANUFACTURING: NON-INDUSTRY PLAYERS 8.1. Chapter Overview 8.2. Center for Cell and Gene Therapy, Baylor College of Medicine, US 8.3. Centre for Cell Manufacturing Ireland, National University of Ireland, Ireland 8.4. Clinical Cell and Vaccine Production Facility, University of Pennsylvania, US 8.5. Guy's And St. Thomas' GMP Facility, Guy's Hospital, UK 8.6. Newcastle Cellular Therapies Facility, Newcastle University, UK 8.7. Rayne Cell Therapy Suite, King's College London, UK 8.8. Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre of Regenerative Medicine, UK 8.9. Laboratory of Cell and Gene Medicine, Stanford University, US

9. ROLE OF NON-PROFIT ORGANIZATIONS 9.1. Chapter overview 9.2. Cell Therapy Manufacturing: List of Non-Profit Organizations 9.3. Cell Therapy Manufacturing: International Societies

10. RECENT DEVELOPMENTS 10.1. Chapter Overview 10.2. Collaboration / Agreement Models 10.3. Cell Therapy Manufacturing: List of Collaborations 10.4. Cell Therapy Manufacturing: Partnership Analysis

11. MARKET SIZING AND FORECAST 11.1. Context and Background 11.2. Forecast Methodology 11.3. Cell Therapy Manufacturing Market, 2017-2027 11.4. Cell Therapy Manufacturing Market: Regional View

12. SWOT ANALYSIS

13. CONCLUSION 13.1. A Growing Pipeline of Cell Therapy Products is Likely to Increase the Demand for Manufacturing of Cell-based Therapies 13.2. Stakeholders are Continuously Striving to Overcome Existing Challenges 13.3. Developed Economies have Emerged as Prominent Hubs for Cell Therapy Manufacturing 13.4. Both Industry and Academia have Jointly Led the Initiatives; The Trend is Likely to Persist in the Near Term 13.5. Partnerships / Collaborations have been Widespread and will Continue to act as Key Enablers 13.6. The Manufacturing of Cell-based Therapies is Likely to Become a Multi-billion Dollar Market in the Coming Decade

14. SURVEY ANALYSIS 14.1. Chapter Overview 14.2. Seniority Level of Respondents 14.3. Type of Cell Therapy 14.4. Scale of Operation 14.5. Source of Cells 14.6. Type of Cell Culture System 14.7. Fill / Finish Service

15. INTERVIEW TRANSCRIPTS 15.1. Chapter Overview 15.2. Tim Oldham, CEO, Cell Therapies 15.3. Brian Dattilo, Manager of Business Development, Waisman Biomanufacturing 15.4. Mathilde Girard, Department Leader, Cell Therapy Innovation and Development, YposKesi 15.5. Dr. Gerard J Bos (CEO, CiMaas)

16. APPENDIX: TABULATED DATA

17. APPENDIX: LIST OF COMPANIES AND RESEARCH ORGANIZATIONS

For more information about this report visit http://www.researchandmarkets.com/research/bvlctq/cell_therapy

Related Articles

Go here to read the rest:
Cell Therapy Manufacturing Market, 2027: Partnerships / Collaborations have been Widespread and will Continue to ... - GlobeNewswire (press release)

Posted in Cell Therapy | Comments Off on Cell Therapy Manufacturing Market, 2027: Partnerships / Collaborations have been Widespread and will Continue to … – GlobeNewswire (press release)

Page 1,624«..1020..1,6231,6241,6251,626..1,6301,640..»